# A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients (PSX-X03)

> **NCT00438009** · PHASE1 · COMPLETED · sponsor: **Viralytics** · enrollment: 9 (actual)

## Conditions studied

- Stage IV Melanoma

## Interventions

- **DRUG:** Coxsackievirus A21

## Key facts

- **NCT ID:** NCT00438009
- **Lead sponsor:** Viralytics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05-16
- **Primary completion:** 2009-08-28
- **Final completion:** 2009-08-28
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2019-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00438009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00438009, "A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients (PSX-X03)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00438009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*